Catalyst
Slingshot members are tracking this event:
AbbVie's HUMIRA (adalimumab) Receives U.S. Food and Drug Administration Approval to Treat Adults with Non-Infectious Intermediate, Posterior and Panuveitis
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ABBV |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 30, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Humira, Adalimumab, Non-infectious Uveitis, Vision Impairment, Non-corticosteroid Therapy, Tnf-α, Visual-i, Visual-ii
